China
1
NMPAMarketing authorization
2
NHSAValue and negotiation
3
NRDLNational reimbursement list
4
Patient accessImplementation
Approval is only the beginning of access.
See how innovative medicines move from regulatory approval through value assessment and price negotiation to real patient access.
🇺🇸🇪🇺🇯🇵🇧🇷🇮🇳🇦🇺Regulatory
HTA
Price
Access
One medicine. Different access logic.
After approval, different institutions, evidence thresholds and negotiation mechanisms determine when patients actually receive treatment.
South Korea
1
MFDSApproval
2
HIRABenefit assessment
3
NHISPrice negotiation
4
MOHWFinal listing
RSA
Australia
1
TGARegistration
2
PBACHTA recommendation
3
PBSPricing and listing
4
Patient accessSubsidized use
Pricing by indication
Special mechanisms often determine the real pathway.
From China's national reimbursement negotiation and Korea's RSA and flexible pricing contracts to Australia's indication-based pricing—the differences need explanation, not just a list.
National reimbursement negotiation
Clinical value + economic evidence
Payment standard + listing
RSA
Payer
Shared uncertainty
Outcome feedback
Flexible price contract
Base price
Use / expenditure signal
Price adjustment
Pricing by indication
Indication
Value difference
Differentiated price
Start with one market. See the complete pathway.
Explore the real decision relationships between regulation, HTA, pricing, reimbursement and post-listing management.